Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease : a dose escalation, open-label, phase 1/2 trial
BACKGROUND: Parkinson's disease is typically treated with oral dopamine replacement therapies; however, long-term treatment leads to motor complications and, occasionally, impulse control disorders caused by intermittent stimulation of dopamine receptors and off-target effects, respectively. We aimed to assess the safety, tolerability, and efficacy of bilateral, intrastriatal delivery of ProSavin,